Catalyst Pharmaceuticals, Inc.

343 articles about Catalyst Pharmaceuticals, Inc.

• Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences - May 17, 2022

  5/17/2022

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences.

• Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

  5/10/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the first quarter 2022 and provided a corporate update.

• Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

  4/25/2022

  Catalyst Pharmaceuticals, Inc. announced that it will release its first-quarter 2022 financial results after market close on Tuesday, May 10, 2022.

• Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/16/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the fourth quarter and full year 2021 and provided a corporate update.

• Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

  3/11/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX),  and KYE Pharmaceuticals Inc. ("KYE"), today announced receipt of a favorable decision from the Federal Court of Canada (“Court”) setting aside for the second time the decision of Canada’s national healthcare regulatory agency, Health Canada, to approve Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome ("LEMS") patients.

• Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

  3/3/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2021 financial results after market close on Wednesday, March 16, 2022.

• Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

  3/2/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has notified Catalyst that an additional patent covering FIRDAPSE®.

• Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

  2/7/2022

  Catalyst Pharmaceuticals, Inc. today provided preliminary 2021 fourth quarter and full year total revenue estimates, a forecast of 2022 total revenue expectations, and a corporate update.

• Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

  2/3/2022

  Catalyst Pharmaceuticals, Inc. today reported that the District Court which heard Catalyst's Lawsuit against the FDA has entered summary judgment in favor of Catalyst.

• Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

  1/4/2022

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate in two upcoming investor conferences.

• 

  Clinical Catch-Up: December 6-10

  12/13/2021

  There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.

• Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

  12/6/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE®.

• Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/15/2021

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021.

• Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

  11/9/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the third quarter ended September 30, 2021, and provided a corporate update.

• Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST

  10/25/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

• Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

  9/30/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®

• Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/17/2021

  Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

• Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences in September 2021

  9/10/2021

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate in two upcoming investor conferences:.

• Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

  8/16/2021

  Catalyst Pharmaceuticals, Inc. today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations.

• Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.